AXIM BIOTECHNOLOGIES, INC. (AXIM)

Every figure this model derived for AXIM, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2024-06-30.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 0 PaymentsToAcquirePropertyPlantAndEquipment 2023-12-31
cash 6,044 CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents 2024-06-30
current assets 20,243 AssetsCurrent 2024-06-30
current liabilities 6,572,371 LiabilitiesCurrent 2024-06-30
equity -9,534,790 StockholdersEquity 2024-06-30
interest expense 210,000 InterestExpenseDebt 2024-06-30
ocf -758,995 NetCashProvidedByUsedInOperatingActivities 2024-06-30
revenue 92,898 Revenues 2024-06-30
sbc 91,727 ShareBasedCompensation 2024-06-30

The ratios

The figures themselves rather than their scores — what somebody looking up AXIM on one particular measure came for.

RatioValue
cash operating margin-1929.11
current ratio0.0
current ratio reported0.0
deferred revenue growth-26.89
fcf margin-817.02
growth cv1.29
interest cover-11.02
operating margin-2490.34
owner earnings margin-915.76
revenue growth254.56
revenue growth per share254.56
rule of 40-2235.78
sbc pct revenue98.74

What to be careful about

What this model itself distrusts about AXIM's figures. Written by the derivation as it ran, not added afterwards.